Quantcast
Home > Quotes > GMDA

Gamida Cell Ltd. Ordinary Shares (GMDA) Quote & Summary Data

GMDA 
$10.8
*  
0.21
1.91%
Get GMDA Alerts
*Delayed - data as of Jan. 18, 2019  -  Find a broker to begin trading GMDA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 11.21 / $ 10.33
Share Volume
8,289
50 Day Avg. Daily Volume
24,738
Previous Close
$ 11.01
52 Week High / Low
$ 15.41 / $ 7.99
Market Cap
261,607,363
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
8,289
50 Day Avg. Daily Volume:
24,738

Trading Range

The current last sale of $10.80 is 35.17% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 11.21 $ 15.41
 Low: $ 10.33 $ 7.99

Company Description (as filed with the SEC)

To deliver curative cell therapies to patients with serious and life-threatening medical conditions. Overview We are a clinical stage biopharmaceutical company leveraging our proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. While cell therapies have the potential to address a variety of diseases, they are limited by availability of donor cells, matching a donor to the patient, and the decline in donor cell functionality when expanding the cells to achieve a therapeutic dose. We have leveraged our nicotinamide-, or NAM-, based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. Our proprietary technology is designed to allow for the proliferation of donor cells while maintaining the cells' functional therapeutic characteristics, which, if approved, will provide a treatment alternative for patients.  ... More ...  


Risk Grade

Where does GMDA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 11.21
Open Date:
Jan. 18, 2019
Close Price:
$ 10.80
Close Date:
Jan. 18, 2019

Consensus Recommendation

Analyst Info